194 related articles for article (PubMed ID: 11005271)
1. Cabergoline modulation of alpha-subunits and FSH secretion in a gonadotroph adenoma.
Giusti M; Bocca L; Florio T; Foppiani L; Corsaro A; Auriati L; Spaziante R; Schettini G; Giordano G
J Endocrinol Invest; 2000; 23(7):463-6. PubMed ID: 11005271
[TBL] [Abstract][Full Text] [Related]
2. In vivo secretory potential and the effect of combination therapy with octreotide and cabergoline in patients with clinically non-functioning pituitary adenomas.
Andersen M; Bjerre P; Schrøder HD; Edal A; Høilund-Carlsen PF; Pedersen PH; Hagen C
Clin Endocrinol (Oxf); 2001 Jan; 54(1):23-30. PubMed ID: 11167922
[TBL] [Abstract][Full Text] [Related]
3. A luteinizing hormone-, alpha-subunit- and prolactin-secreting pituitary adenoma responsive to somatostatin analogs: in vivo and in vitro studies.
Saveanu A; Morange-Ramos I; Gunz G; Dufour H; Enjalbert A; Jaquet P
Eur J Endocrinol; 2001 Jul; 145(1):35-41. PubMed ID: 11415850
[TBL] [Abstract][Full Text] [Related]
4. The effect of thyrotropin-releasing hormone on gonadotropin and free alpha-subunit secretion in patients with acromegaly and functionless pituitary tumors.
Popovic V; Damjanovic S
Thyroid; 1998 Oct; 8(10):935-9. PubMed ID: 9827662
[TBL] [Abstract][Full Text] [Related]
5. Effects of somatostatin-14 and the receptor-specific somatostatin analogs on chromogranin A and alpha-subunit (alpha-SU) release from "clinically nonfunctioning" pituitary adenoma cells incubated in vitro.
Pawlikowski M; Lawnicka H; Pisarek H; Kunert-Radek J; Radek M; Culler MD
J Physiol Pharmacol; 2007 Mar; 58(1):179-88. PubMed ID: 17440235
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas.
Saveanu A; Gunz G; Guillen S; Dufour H; Culler MD; Jaquet P
Neuroendocrinology; 2006; 83(3-4):258-63. PubMed ID: 17047391
[TBL] [Abstract][Full Text] [Related]
7. Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatins.
Gatto F; Barbieri F; Gatti M; Wurth R; Schulz S; Ravetti JL; Zona G; Culler MD; Saveanu A; Giusti M; Minuto F; Hofland LJ; Ferone D; Florio T
Clin Endocrinol (Oxf); 2012 Mar; 76(3):407-14. PubMed ID: 21848909
[TBL] [Abstract][Full Text] [Related]
8. Combined beta FSH and beta LH response to TRH in patients with clinically non-functioning pituitary adenomas.
Somjen D; Tordjman K; Kohen F; Baz M; Razon N; Ouaknine G; Stern N
Clin Endocrinol (Oxf); 1997 May; 46(5):555-62. PubMed ID: 9231051
[TBL] [Abstract][Full Text] [Related]
9. Ovarian hyperstimulation without elevated serum estradiol associated with pure follicle-stimulating hormone-secreting pituitary adenoma.
Shimon I; Rubinek T; Bar-Hava I; Nass D; Hadani M; Amsterdam A; Harel G
J Clin Endocrinol Metab; 2001 Aug; 86(8):3635-40. PubMed ID: 11502789
[TBL] [Abstract][Full Text] [Related]
10. Effects of cabergoline in a pituitary adenoma secreting follicle-stimulating hormone.
Leese G; Jeffreys R; Vora J
Postgrad Med J; 1997 Aug; 73(862):507-8. PubMed ID: 9307745
[TBL] [Abstract][Full Text] [Related]
11. Long-term effects of a gonadotrophin-releasing hormone agonist ([D-Ser(But)6]GnRH(1-9)nonapeptide-ethylamide) on gonadotrophin secretion from human pituitary gonadotroph cell adenomas in vitro.
Daniels M; Newland P; Dunn J; Kendall-Taylor P; White MC
J Endocrinol; 1988 Sep; 118(3):491-6. PubMed ID: 2460576
[TBL] [Abstract][Full Text] [Related]
12. In vitro detection of glycoprotein production and secretion by human nonfunctioning pituitary adenomas.
Saccomanno K; Gil del Alamo P; Bassetti M; Reza-Elahi F; Spada A
J Endocrinol Invest; 1993 Feb; 16(2):109-15. PubMed ID: 7681860
[TBL] [Abstract][Full Text] [Related]
13. Abnormal response of luteinizing hormone beta subunit to thyrotrophin-releasing hormone in patients with non-functioning pituitary adenoma.
Gil-del-Alamo P; Pettersson KS; Saccomanno K; Spada A; Faglia G; Beck-Peccoz P
Clin Endocrinol (Oxf); 1994 Nov; 41(5):661-6. PubMed ID: 7828356
[TBL] [Abstract][Full Text] [Related]
14. Pituitary macroadenoma secreting thyrotropin and growth hormone: remission of bihormonal hypersecretion in response to lanreotide therapy.
Shimon I; Nass D; Gross DJ
Pituitary; 2001 Sep; 4(4):265-9. PubMed ID: 12501978
[TBL] [Abstract][Full Text] [Related]
15. [Gonadotroph pituitary adenomas].
Chanson P
Ann Endocrinol (Paris); 2000 Sep; 61(3):258-68. PubMed ID: 10970952
[TBL] [Abstract][Full Text] [Related]
16. Gonadotroph adenoma with secondary hypersecretion of testosterone.
Chamoun R; Layfield L; Couldwell WT
World Neurosurg; 2013 Dec; 80(6):900.e7-11. PubMed ID: 23201183
[TBL] [Abstract][Full Text] [Related]
17. Non-functioning pituitary adenomas.
Chanson P; Brochier S
J Endocrinol Invest; 2005; 28(11 Suppl International):93-9. PubMed ID: 16625856
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of cabergoline in reducing follicle-stimulating hormone and prolactin hypersecretion from pituitary macroadenoma in an infertile woman.
Paoletti AM; Depau GF; Mais V; Guerriero S; Ajossa S; Melis GB
Fertil Steril; 1994 Oct; 62(4):882-5. PubMed ID: 7926104
[TBL] [Abstract][Full Text] [Related]
19. In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy.
Ferone D; Pivonello R; Lastoria S; Faggiano A; Del Basso de Caro ML; Cappabianca P; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2001 Apr; 54(4):469-77. PubMed ID: 11318782
[TBL] [Abstract][Full Text] [Related]
20. Short-term pre-surgical treatment with somatostatin analogues, octreotide and lanreotide, in acromegaly.
Waśko R; Ruchała M; Sawicka J; Kotwicka M; Liebert W; Sowiński J
J Endocrinol Invest; 2000 Jan; 23(1):12-8. PubMed ID: 10698045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
